{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06313593",
            "orgStudyIdInfo": {
                "id": "INCB160058-101"
            },
            "organization": {
                "fullName": "Incyte Corporation",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms",
            "officialTitle": "A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-evaluate-the-safety-tolerability-of-in-participants-with-myeloproliferative-neoplasms"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-22",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-06-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-09-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-08",
            "studyFirstSubmitQcDate": "2024-03-14",
            "studyFirstPostDateStruct": {
                "date": "2024-03-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Incyte Corporation",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms."
        },
        "conditionsModule": {
            "conditions": [
                "Myeloproliferative Neoplasms"
            ],
            "keywords": [
                "Myeloproliferative Neoplasms",
                "INCB160058",
                "Myelofibrosis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 66,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1 Dose Escalation - with MF",
                    "type": "EXPERIMENTAL",
                    "description": "INCB160058 will be administered at a protocol defined starting regimen to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\\[s\\]). Participants with myelofibrosis (MF) will enroll in this group.",
                    "interventionNames": [
                        "Drug: INCB160058"
                    ]
                },
                {
                    "label": "Part 2 Dose Expansion - with MF",
                    "type": "EXPERIMENTAL",
                    "description": "INCB160058 will be administered at the RDE(s) identified during Part 1. Participants with MF will enroll in this group.",
                    "interventionNames": [
                        "Drug: INCB160058"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "INCB160058",
                    "description": "Oral; Tablet",
                    "armGroupLabels": [
                        "Part 1 Dose Escalation - with MF",
                        "Part 2 Dose Expansion - with MF"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with Dose Limiting Toxicities (DLTs)",
                    "description": "Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Number of participants with Treatment-emergent Adverse Events (TEAEs)",
                    "description": "Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.",
                    "timeFrame": "Up to 2 years and 30 days"
                },
                {
                    "measure": "Number of participants with TEAEs leading to dose modification or discontinuation",
                    "description": "Number of participants with TEAEs leading to dose modification or discontinuation.",
                    "timeFrame": "Up to 2 years and 30 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "INCB160058 pharmacokinetic (PK) in Plasma",
                    "description": "INCB160058 concentration in plasma.",
                    "timeFrame": "Up to Day 57"
                },
                {
                    "measure": "Response using the revised IWG-MRT and ELN response criteria for MF",
                    "description": "Defined as the percentage of participants with Response using the revised International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) response criteria.",
                    "timeFrame": "Week 12 and 24 and then every 24 weeks up to 2 years"
                },
                {
                    "measure": "Percentage of participants achieving spleen volume reduction as defined in the protocol",
                    "description": "Defined as percentage of participants with a protocol defined Spleen Volume Reduction.",
                    "timeFrame": "Week 12 and Week 24"
                },
                {
                    "measure": "Percentage of participants achieving \u2265 50% reduction from baseline of total symptom score (TSS)",
                    "description": "Defined as the percentage of participants achieving \u2265 50% reduction from baseline of TSS.",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Participants with MF with symptomatic anemia: Anemia Response",
                    "description": "For non transfusion-dependent (TD) participants: A hemoglobin increase relative to baseline as defined in the protocol if non-TD at baseline. For TD participants: Achieving transfusion independency (TI) as defined in the protocol.",
                    "timeFrame": "Up to 2 years and 30 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years\n* Participants with intermediate-1 or higher risk PMF, post-PV, of post-ET MF, histologically confirmed\n* Evidence of minimum burden of disease based on symptoms and/or splenomegaly\n* Life expectancy \\> 6 months\n* Willingness to undergo a pretreatment and regular on-study bone marrow biopsies and aspirations (as appropriate to disease)\n* Existing documentation of JAK2V617F mutation from a qualified local laboratory\n* Previously treated with at least 1 JAK inhibitor for \u2265 12 weeks and resistant, refractory, intolerant to, or have lost response to JAK inhibitor treatment\n\nExclusion Criteria:\n\n* Presence of a hematological malignancy requiring treatment, other than PMF, post-PV MF, or post-ET MF\n* Prior history of major bleeding or thrombosis within the 3 months prior to study enrollment\n* Participants with abnormal hematologic, hepatic, or renal function based on laboratory evaluation\n* Has undergone prior allogenic or autologous stem-cell transplantation or allogenic stem-cell transplantation is planned\n* Active invasive malignancy\n* Significant concurrent, uncontrolled medical condition\n* Active HBV/HCV or known HIV\n* Any prior MF-directed therapy within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment\n* Participants undergoing treatment with G-CSF or GM-CSF, romiplostim, or eltrombopag at any time within 4 weeks before the first dose of study treatment\n\nOther protocol-defined Inclusion/Exclusion Criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Incyte Corporation Call Center (US)",
                    "role": "CONTACT",
                    "phone": "1.855.463.3463",
                    "email": "medinfo@incyte.com"
                },
                {
                    "name": "Incyte Corporation Call Center (ex-US)",
                    "role": "CONTACT",
                    "phone": "+800 00027423",
                    "email": "eumedinfo@incyte.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Incyte Medical",
                    "affiliation": "Incyte Corporation",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford University",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94304",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                },
                {
                    "facility": "Northwestern University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "The University of Kansas Cancer Center Kucc University of Kansas Clinical Research Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Fairway",
                    "state": "Kansas",
                    "zip": "66205",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.02223,
                        "lon": -94.6319
                    }
                },
                {
                    "facility": "Icahn School of Medicine At Mount Sinai",
                    "status": "NOT_YET_RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Sloan Kettering Institute For Cancer Research",
                    "status": "NOT_YET_RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Oregon Health & Science University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Vanderbilt Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Md Anderson Cancer Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009196",
                    "term": "Myeloproliferative Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12149",
                    "name": "Myeloproliferative Disorders",
                    "asFound": "Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28312",
                    "name": "Primary Myelofibrosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T1311",
                    "name": "Chronic Myeloproliferative Disorders",
                    "asFound": "Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4705",
                    "name": "Primary Myelofibrosis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}